Christopher Loynd, DO
Psychiatry · Saint Louis, MONPI 1003965955
Payments from drug & device makers
Across 590 payments — averaging $449.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$223K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$30K
- Sunovion Pharmaceuticals Inc.$9K
- Alkermes, Inc.$786
- Otsuka America Pharmaceutical, Inc.$658
- AbbVie$410
- plus $2K from 16 others
What the payments were for
- Consulting fees$6,2502%
- Speaking & faculty fees$223,10884%
- Travel & lodging$24,4049%
- Food & beverage$11,4364%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 352 | $222,702 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $30,073 |
| Sunovion Pharmaceuticals Inc. | 9 | $8,948 |
| Alkermes, Inc. | 36 | $786 |
| Otsuka America Pharmaceutical, Inc. | 37 | $658 |
| AbbVie(2 entities) | 30 | $410 |
| Teva Pharmaceuticals USA, Inc. | 15 | $317 |
| Neurocrine Biosciences, Inc. | 18 | $289 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $224 |
| Vanda Pharmaceuticals Inc. | 8 | $159 |
| Luye Pharma (USA) Ltd. | 3 | $137 |
| Ironshore Pharmaceuticals Inc. | 3 | $137 |
| AstraZeneca | 1 | $111 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Lundbeck LLC | 2 | $30 |
| Almatica Pharma LLC | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $19 |
| Bausch Health US, LLC | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$212,777
- INVEGA TRINZA$210,152
- CAPLYTA$29,068
- LATUDA$8,849
- SPRAVATO$3,374
- ARISTADA$939
- ABILIFY MAINTENA$125
- LYBALVI$125
- ERZOFRI EXTENDED-RELEASE$123
- FARXIGA$111
- ARISTADA INITIO$110
- Jornay PM 20mg capsules (Bottle of 100)$103
How this compares
$265,198 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 43 | $334,144 |
| Invega TrinzaPaliperidone Palmitate | 22 | $197,049 |
| Lurasidone Hcl | 174 | $68,961 |
| Invega SustennaPaliperidone Palmitate | 28 | $64,083 |
| VraylarCariprazine Hcl | 29 | $44,618 |
| Abilify MaintenaAripiprazole | 13 | $32,655 |
| CaplytaLumateperone Tosylate | 15 | $29,180 |
| TrintellixVortioxetine Hydrobromide | 31 | $15,228 |
| Quetiapine Fumarate | 365 | $7,703 |
| Aripiprazole | 136 | $5,533 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $3,306 |
| Hydroxyzine Hcl | 139 | $3,256 |
| Buspirone Hcl | 231 | $3,108 |
| Ziprasidone Hcl | 25 | $2,986 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $2,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $289 | $334,14443 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $222,702 | $261,13350 claims |
| AbbVieVraylar | $410 | $44,61829 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $658 | $32,65513 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $30,073 | $29,18015 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $224 | $15,22831 claims |
| Almatica Pharma LLCSertraline Hcl | $29 | $1,273254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Junaid SyedSaint Louis$8M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mary KimmelSaint Louis$539K
- George GrossbergSaint Louis$521K
- Asif HabibSaint Louis$517K
- Eric LenzeSaint Louis$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.